Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

107.89 -1.86 (-1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
Via Benzinga
Axsome Stock Rockets To Record High After Settling With Teva Over Depression Drug, Retail Optimism Swells
Under the settlement terms, Teva will receive a license to sell a generic version of Auvelity starting March 31, 2039, if pediatric exclusivity is granted. 
Via Stocktwits
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
From Axsome Therapeutics, Inc.
Via GlobeNewswire
12 Analysts Have This To Say About Axsome Therapeutics
Via Benzinga
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Via Benzinga
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Via Benzinga
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
Exposures Product Safety
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. 
Via Investor's Business Daily
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile. 
Via Benzinga
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
From Axsome Therapeutics, Inc.
Via GlobeNewswire
1 Under-the-Radar Biotech Stock to Buy and Hold
It could be an industry giant in the making. 
Via The Motley Fool
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
FDA sets PDUFA action goal date of January 31, 2025 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Participate in Investor Conferences in September
From Axsome Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS